SecBot SecBot
PRESS-RELEASE ·Filed Jun 3, 2026

DRTS

Alpha Tau Medical Ltd.; Tolmar Inc.
BULLISH
Impact 7/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

The deal provides near-term capital and long-term revenue potential, but the stock has already rallied ~25% on prior reports. Monitor for FDA trial progress and milestone triggers. The 60% net sales margin is highly favorable for Alpha Tau, but commercialization risk remains pre-approval.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.58
T+0 close · Jun 3, 2026 · via day close
Latest settled
+39.98%
T+60 · $14.81
Vs SPY
+37.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $10.58entry
  2. T+1 · 6mo ago −2.74%α −3.14% · $10.29
  3. T+5 · 5mo ago −12.67%α −8.85% · $9.24
  4. T+20 · 5mo ago +25.05%α +26.05% · $13.23
  5. T+60 · 3mo ago +39.98%α +37.48% · $14.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau Medical announced a strategic collaboration with Tolmar Inc. for exclusive U.S. commercialization of Alpha DaRT in prostate cancer, with an option for bladder cancer. Tolmar will invest $20M at an $11.99/share premium (25% above 30-day VWAP), pay $15M for manufacturing capacity, and provide up to $161.5M in milestones. The deal validates Alpha Tau's platform and provides non-dilutive capital, but the stock is already up significantly on prior reports.

Key Financial Metrics

Deal Value
$161.5M

Key Facts

  • Tolmar gets exclusive U.S. commercialization rights for prostate cancer (20-year term from first sale) with option for bladder cancer.
  • Tolmar makes $20M equity investment at $11.99/share (25% premium to 30-day VWAP) and $15M manufacturing facility investment.
  • Up to $161.5M in clinical, regulatory, and commercial milestones for the first indication.
  • Alpha Tau will manufacture Alpha DaRT and sell to Tolmar at 60% of net sales price (subject to adjustments).
  • Tolmar holds right of first negotiation on new Alpha Tau products for U.S. urological cancers.

Financial Impact

Immediate $20M equity infusion at premium + $15M manufacturing investment; up to $161.5M in milestones; 60% net sales revenue share for Alpha Tau.

revenuecashdilution

Risk Factors

  • Alpha DaRT is still in clinical development; no guarantee of FDA approval.
  • Milestone payments are contingent on achieving clinical/regulatory targets.
  • Dilution from $20M equity investment at $11.99/share (though at premium).

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3306041

US Market Status

Market Closed · Opens in 7h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026